{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:38:55Z","timestamp":1751279935982,"version":"3.37.3"},"reference-count":44,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"unspecified","delay-in-days":74,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2021,12,2]]},"DOI":"10.1080\/14737140.2021.1971520","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T08:17:27Z","timestamp":1629879447000},"page":"1411-1422","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0312-5891","authenticated-orcid":false,"given":"Frederick W","family":"Thielen","sequence":"first","affiliation":[{"name":"Section Health Technology Assessment, Erasmus School of Health Policy and Management\/Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie-Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"Division of Haematology, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pim","family":"Kuizenga","sequence":"additional","affiliation":[{"name":"Celgene BV A Bristol Myers Squibb Company, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-2592","authenticated-orcid":false,"given":"Mels","family":"Hoogendoorn","sequence":"additional","affiliation":[{"name":"Division of Haematology, Medical Center Leeuwarden, Leeuwarden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0882-2346","authenticated-orcid":false,"given":"Eduardus FM","family":"Posthuma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Leiden University Medical Center & Reinier de Graaf Hospital, Delft, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy BC","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5808-302X","authenticated-orcid":false,"given":"Carin","family":"A Uyl-de Groot","sequence":"additional","affiliation":[{"name":"Section Health Technology Assessment, Erasmus School of Health Policy and Management\/Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-0531","authenticated-orcid":false,"given":"Hedwig M","family":"Blommestein","sequence":"additional","affiliation":[{"name":"Section Health Technology Assessment, Erasmus School of Health Policy and Management\/Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24937"},{"key":"cit0002","unstructured":"Dinnessen M, Brink M, Korf-van Vliet C, et al. Het folliculair lympfoom in Nederland, 2014-2016. Landelijk rapport van het hematooncologieregister van de Nederlandse Kankerregistratie. [Internet]. 2019 [cited 2020 Apr 21]. Available from: https:\/\/www.iknl.nl\/getmedia\/6fbcaf47-2677-4b4e-933d-68d5be07773b\/Hematologische_kankersoorten_landelijk_rapport_iknl_FL_2014_2016.pdf."},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/acg2.74"},{"key":"cit0004","unstructured":"Anonymous. Zevalin [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 30]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zevalin."},{"key":"cit0005","unstructured":"Anonymous. Zydelig [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 30]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zydelig."},{"key":"cit0006","unstructured":"Anonymous. Gazyvaro [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 30]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gazyvaro."},{"key":"cit0007","unstructured":"Anonymous. MabThera [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 29]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera."},{"key":"cit0008","unstructured":"Anonymous. IntronA [Internet]. Eur. Med. Agency. 2018 [cited 2020 Mar 29]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/introna."},{"key":"cit0009","unstructured":"European Medicines Agency. EMA\/225905\/2019. Revlimid (lenalidomide) [Internet]. [cited 2019 Dec 2]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/revlimid-epar-medicine-overview_en.pdf."},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00448-8"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1002\/hon.45_2630"},{"key":"cit0014","first-page":"1","author":"Dhanasiri S","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"cit0015","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"Briggs A","year":"2006"},{"key":"cit0016","unstructured":"Drummond MF, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes [Internet]. Oxford: Oxford University Press; 2015 [cited 2020 Mar 26]. Available from: 10.1136\/jech.41.4.355-a."},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00123.x"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(96)00507-3"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2008.07.007"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0749-8"},{"key":"cit0021","unstructured":"PAID [version 3.0] [Internet]. iMTA. [cited 2020 Mar 26]. Available from: https:\/\/www.imta.nl\/paid\/."},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.2165\/11586130-000000000-00000"},{"volume-title":"Practical guidance for including future costs in economic evaluations","author":"Kellerborg K","key":"cit0023"},{"key":"cit0024","unstructured":"Woods B, Sideris E, Palmer S, et al. Partitioned survival analysis for decision modelling in health care: a critical review report. NICE Decis Support Unit. 2017;1\u201372."},{"key":"cit0025","volume":"1","author":"Hakkaart-van Roijen L","year":"2016","journal-title":"Bijlage"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"cit0027","unstructured":"Z-Index - About [Internet]. [cited 2020 Mar 26]. Available from: https:\/\/www.z-index.nl\/english."},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000648"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903149479"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-84"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003712258"},{"key":"cit0032","unstructured":"Nederlandse Vereniging voor Hematologie. Richtlijn voor de diagnostiek, behandeling en follow-up van het folliculair lymfoom [Internet]. 2020 [cited 2020 Feb 19]. Available from: http:\/\/www.hovon.nl\/upload\/File\/Richtlijnen_BehAdv\/FL%20richtlijn_revisie2019.pdf."},{"key":"cit0033","unstructured":"Statistics Netherlands. Open data [Internet]. Stat. Neth. [cited 2020 Mar 27]. Available from: https:\/\/www.cbs.nl\/en-gb\/our-services\/open-data."},{"key":"cit0034","unstructured":"The iMTA disease burden calculator [version 1.3 beta] [Internet]. [cited 2020 Mar 26]. Available from: www.imta.nl\/idbc."},{"key":"cit0035","unstructured":"Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg [Internet]. 2016 [cited 2020 Mar 11]. Available from: https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg."},{"key":"cit0036","first-page":"1109","volume":"89","author":"Doorduijn JK","year":"2004","journal-title":"Haematologica"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S134603"},{"key":"cit0038","unstructured":"Single Technology Appraisal. Lenalidomide for treated follicular lymphoma and marginal zone lymphoma [ID1374]. Committee Papers [Internet]. National Institute for Health and Care Excellence; 2020 [cited 2020 Mar 30]. Available from: https:\/\/www.nice.org.uk\/guidance\/gid-ta10323\/documents\/committee-papers."},{"key":"cit0039","unstructured":"Final appraisal document. Lenalidomide with rituximab for previously treated follicular lymphoma. [Internet]. National Institute for Health and Care Excellence; 2020 [cited 2020 Mar 30]. Available from: https:\/\/www.nice.org.uk\/guidance\/gid-ta10323\/documents\/final-appraisal-determination-document."},{"key":"cit0040","doi-asserted-by":"crossref","unstructured":"Zhang P-F, Xie D, Wen F, et al. Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: a cost-effectiveness analysis. Cancer Med [Internet]. [cited 2020 Jun 17];n\/a. Available from: 10.1002\/cam4.3121.","DOI":"10.1002\/cam4.3121"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)63491-2"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00204-z"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"cit0044","unstructured":"van Rijn M. Regeling van de Minister voor Medische Zorg van 18 mei 2020, kenmerk 1687653-205139-Z, houdende wijziging van de Regeling zorgverzekering in verband met de opname van het geneesmiddel lenalidomide in het basispakket. Staatscourant; 2020."}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2021.1971520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T21:06:23Z","timestamp":1699391183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2021.1971520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,2]]}},"alternative-id":["10.1080\/14737140.2021.1971520"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2021.1971520","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"type":"print","value":"1473-7140"},{"type":"electronic","value":"1744-8328"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}